Completed PHASE2 INTERVENTIONAL NCT00102479

Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents

A Phase II Study to Test PK Tolerability in Children and Adolescents

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Updated 5 times since 2017 Last updated: Apr 13, 2006 Started: Jul 31, 2004 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00102479, this PHASE2 trial focuses on Mania and Schizophrenia and remains completed. Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., it has been updated 5 times since 2004, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Data source: Otsuka Pharmaceutical Development & Commercialization, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.